56 results
8-K
EX-99.1
LQDA
Liquidia Corp
6 Sep 23
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
4:37pm
Exhibit 99.1
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office … this lawsuit alleging that YUTREPIA infringes this same patent that has already been litigated and already found by the PTAB to be invalid, it was expected. We
8-K
EX-99.1
LQDA
Liquidia Corp
1 Apr 24
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
7:00am
the injunction that was issued in August 2022 in the lawsuit filed by United Therapeutics (UTHR) in Case No. 1:20-cv-00755-RGA (the Original Hatch-Waxman … action, UTHR filed a lawsuit against FDA in the U.S. District Court for the District of Columbia (Case No. 24-484), and a motion for a temporary
8-K
EX-99.1
LQDA
Liquidia Corp
13 May 24
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
6:24pm
.
Awaiting ruling from District Court on preliminary injunction in new patent infringement lawsuit filed by United Therapeutics. United Therapeutics filed … a new patent infringement lawsuit against the company in Delaware District Court (Case No. 1:23-cv-00975-RGA) alleging that YUTREPIA infringes U.S
8-K
LQDA
Liquidia Corp
1 Apr 24
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
7:00am
”).
In the first action, United Therapeutics filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (the “D.C. District … Bates, who is presiding over this lawsuit in the D.C. District Court, denied United Therapeutics’ motion. The D.C. District Court has scheduled a status
S-4
EX-10.37
LQDA
Liquidia Corp
5 Aug 20
Registration of securities issued in business combination transactions
12:00am
ambulatory infusion pump with treprostinil.
1.89 ‘Enforcement Action’ means the claims in the lawsuit brought by Sandoz and RareGen against United … -cv-10170) as of the date of this Amendment, or any other claims brought by Sandoz and/or RareGen in such lawsuit after the date hereof or in any
8-K
EX-99.1
hk28h
29 Dec 21
Stipulation of Partial Judgment In Favor of Liquidia Filed in Hatch-Waxman Litigation
4:16pm
8-K
EX-99.1
76qu7igufok070w 88x
19 Jul 22
Liquidia Receives Favorable Ruling in Inter Partes Review
5:27pm
8-K
p0za9a5deh m0e69
8 Apr 22
Other Events
5:00pm
8-K
EX-99.1
lwvrd
12 Aug 21
U.S. Patent Trial and Trademark Appeal Board Decides to Institute
4:57pm
8-K
EX-99.1
xx8vfyt0lv
13 Oct 21
Liquidia Receives Favorable Ruling in Inter Partes Review
12:00am
8-K
EX-99.1
wtc tnc0xzk6
20 Dec 23
Other Events
5:16pm
8-K
mi7t26s616
13 Dec 21
Other Events
5:06pm
8-K
cek0jb 679f
8 Nov 21
FDA Grants Tentative Approval for Liquidia’s
4:16pm
8-K
xjy0m1 mh74
14 Mar 22
Other Events
7:30am
8-K
quru x3tgv9tl5goruj
20 Dec 23
Other Events
5:16pm
8-K
v6v41mao
23 Jan 24
Other Events
7:30am